Table 2 |
||||
|
Protease Inhibitor treatment received by HIV-2 infected individuals |
||||
| Patient |
Protease Inhibitor |
CD4 (cells/μl) |
Viral load (Log10) |
Therapeutic failure |
|
|
||||
| MRT-1 |
NFV |
173 |
3.9 |
yes |
| MRT-7 |
RTV, NFV |
335 |
4.5 |
yes |
| MRT-8 |
SQV, IDV/rtv, NFV |
211 |
5.3 |
yes |
| MRT-20 |
IDV, NFV |
229 |
2 |
no |
| MRT-22 |
NFV, LPV |
106 |
3.9 |
yes |
| MRT-25 |
IDV, LPV/rtv, APV/rtv |
82 |
3.9 |
yes |
| MRT-29 |
NFV |
53 |
4.5 |
yes |
|
|
||||
|
The Protease Inhibitors sequentially received by each patient from a previous cohort [6] are listed. (For this study, blood samples were taken on April 2002 for MRT-1, March 2002 for MRT-7, June 2003 for MRT-8, December 2000 for MRT-20, June 2002 for MRT-22, February 2003 for MRT-25, and May 2002 for MRT-29). Therapeutic failure was defined when the CD4 counts were < 200 and/or the viral load remained unchanged after treatment [6]. |
||||
|
M'Barek et al. Retrovirology 2006 3:58 doi:10.1186/1742-4690-3-58 |
||||
